Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WAJEEHA YOUSAF

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1770715765
CMS profile
170886
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,769.85

77 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,769.85 77

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WAJEEHA YOUSAF

NPI 1770715765 · CMS profile ID 170886

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770715765?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WAJEEHA YOUSAF, NPI 1770715765, CMS profile ID 170886. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770715765?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). WAJEEHA YOUSAF, NPI 1770715765, CMS profile ID 170886. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770715765?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
WAJEEHA YOUSAF, NPI 1770715765, CMS profile ID 170886, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1770715765?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

77 matching records · $1,769.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 77 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–77 of 77.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $25.0006/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933776703 CMS
Janssen Biotech, Inc. $28.4805/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886619007 CMS
ABBVIE INC. $26.4705/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893255281 CMS
ABBVIE INC. $25.4505/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893255279 CMS
AstraZeneca Pharmaceuticals LP $16.0105/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914886067 CMS
Horizon Therapeutics plc $18.8605/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937715151 CMS
Janssen Biotech, Inc. $22.1705/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886619001 CMS
ABBVIE INC. $28.1404/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893255277 CMS
Hikma Pharmaceuticals USA $15.3004/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927083135 CMS
Janssen Biotech, Inc. $15.8204/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886618995 CMS
ABBVIE INC. $119.8703/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893255275 CMS
AstraZeneca Pharmaceuticals LP $15.8903/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915469679 CMS
ABBVIE INC. $28.5203/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893255273 CMS
ABBVIE INC. $25.0903/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893255271 CMS
Aurinia Pharma U.S., Inc. $27.4803/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954108321 CMS
ABBVIE INC. $23.1203/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893255269 CMS
Amgen Inc. $14.2303/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939343501 CMS
GlaxoSmithKline, LLC. $16.0803/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944821817 CMS
ABBVIE INC. $25.3902/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893255267 CMS
Octapharma USA, Inc. $32.1402/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937558835 CMS
Amgen Inc. $22.3602/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939343499 CMS
Janssen Biotech, Inc. $18.1102/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886618987 CMS
ABBVIE INC. $15.0902/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893255265 CMS
ABBVIE INC. $22.6101/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893255263 CMS
ABBVIE INC. $26.5901/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893255261 CMS
AstraZeneca Pharmaceuticals LP $63.5601/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914793999 CMS
ABBVIE INC. $18.0701/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893255259 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,129.64 99
PY2020 $577.47 23
PY2021 $1,268.96 49
PY2022 $1,769.85 77
PY2023 $6,072.81 80
PY2024 $1,963.83 81
PY2025 $12,690.96 106

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,068,306.54 110
PY2024 Principal investigator $180,496.46 4
PY2023 Principal investigator $19,092.66 4
PY2022 Principal investigator $21,836.00 5
PY2021 Principal investigator $5,568.88 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

110 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARGENX US, INC. $941.00 12/24/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155453
Principal investigator 1 ARGENX US, INC. $4,859.00 12/24/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155464
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,617.31 12/17/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289912
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,195.57 12/17/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289914
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,700.35 12/01/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289142
Principal investigator 1 UCB SA $27,667.00 11/27/2025 Non-covered Recipient Entity
Novel Research Llc
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246656866
Principal investigator 1 ARGENX US, INC. $9,027.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155377
Principal investigator 1 ARGENX US, INC. $9,027.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155381
Principal investigator 1 ARGENX US, INC. $6,519.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155387
Principal investigator 1 ARGENX US, INC. $6,519.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155391
Principal investigator 1 ARGENX US, INC. $2,444.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155396
Principal investigator 1 ARGENX US, INC. $6,519.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155399
Principal investigator 1 ARGENX US, INC. $2,720.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155403
Principal investigator 1 ARGENX US, INC. $4,859.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155406
Principal investigator 1 ARGENX US, INC. $2,444.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155410
Principal investigator 1 ARGENX US, INC. $2,720.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155414
Principal investigator 1 ARGENX US, INC. $941.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155417
Principal investigator 1 ARGENX US, INC. $941.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155421
Principal investigator 1 ARGENX US, INC. $941.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155425
Principal investigator 1 ARGENX US, INC. $2,622.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155460
Principal investigator 1 ARGENX US, INC. $6,519.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155473
Principal investigator 1 ARGENX US, INC. $6,519.00 11/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155478
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24,808.26 11/19/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288597
Principal investigator 1 ARGENX US, INC. $8,393.00 10/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155467
Principal investigator 1 ARGENX US, INC. $2,622.00 10/20/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155470
Principal investigator 1 ARGENX US, INC. $2,622.00 10/02/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155374
Principal investigator 1 ARGENX US, INC. $6,519.00 10/02/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155428
Principal investigator 1 ARGENX US, INC. $6,519.00 10/02/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155431
Principal investigator 1 ARGENX US, INC. $941.00 10/02/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155435
Principal investigator 1 ARGENX US, INC. $941.00 10/02/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155438
Principal investigator 1 ARGENX US, INC. $941.00 10/02/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155441
Principal investigator 1 ARGENX US, INC. $941.00 10/02/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155446
Principal investigator 1 ARGENX US, INC. $941.00 10/02/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155449
Principal investigator 1 ARGENX US, INC. $8,393.00 10/02/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155457
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,288.60 09/17/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285594
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,044.02 09/17/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285596
Principal investigator 1 Novartis Pharmaceuticals Corporation $66,369.68 09/15/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190311937
Principal investigator 1 ARGENX US, INC. $6,519.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155580
Principal investigator 1 ARGENX US, INC. $6,519.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155587
Principal investigator 1 ARGENX US, INC. $4,859.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155591
Principal investigator 1 ARGENX US, INC. $4,859.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155595
Principal investigator 1 ARGENX US, INC. $6,519.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155599
Principal investigator 1 ARGENX US, INC. $6,519.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155602
Principal investigator 1 ARGENX US, INC. $2,622.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155606
Principal investigator 1 ARGENX US, INC. $2,720.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155610
Principal investigator 1 ARGENX US, INC. $2,720.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155613
Principal investigator 1 ARGENX US, INC. $9,027.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155620
Principal investigator 1 ARGENX US, INC. $9,027.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155624
Principal investigator 1 ARGENX US, INC. $941.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155629
Principal investigator 1 ARGENX US, INC. $8,350.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155632
Principal investigator 1 ARGENX US, INC. $2,622.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155637
Principal investigator 1 ARGENX US, INC. $2,444.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155641
Principal investigator 1 ARGENX US, INC. $8,350.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155674
Principal investigator 1 ARGENX US, INC. $2,622.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155682
Principal investigator 1 ARGENX US, INC. $2,444.00 09/04/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155686
Principal investigator 1 ARGENX US, INC. $573.00 09/03/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155690
Principal investigator 1 ARGENX US, INC. $79.50 09/03/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155694
Principal investigator 1 ARGENX US, INC. $143.20 09/03/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155699
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,482.12 08/20/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284395
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,953.58 08/19/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) No dispute reported 06/30/2026 1190311939
Principal investigator 1 ARGENX US, INC. $1,500.00 08/13/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155567
Principal investigator 1 ARGENX US, INC. $600.00 08/13/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155571
Principal investigator 1 ARGENX US, INC. $2,600.00 08/13/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155644
Principal investigator 1 ARGENX US, INC. $16,500.00 08/13/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155647
Principal investigator 1 ARGENX US, INC. $2,350.00 08/13/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155652
Principal investigator 1 ARGENX US, INC. $3,150.00 08/13/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155657
Principal investigator 1 ARGENX US, INC. $250.00 08/13/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155660
Principal investigator 1 ARGENX US, INC. $2,000.00 08/13/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155663
Principal investigator 1 ARGENX US, INC. $2,816.00 08/13/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155667
Principal investigator 1 ARGENX US, INC. $3,000.00 08/13/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155671
Principal investigator 1 ARGENX US, INC. $2,350.00 08/13/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155678
Principal investigator 1 UCB SA $35,544.05 08/13/2025 Non-covered Recipient Entity
Novel Research Llc
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246656604
Principal investigator 1 ARGENX US, INC. $350.00 07/28/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155575
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,245.00 07/25/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283172
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,360.00 07/25/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283174
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 07/25/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283176
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 07/25/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283178
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $232.00 07/25/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283180
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58.00 07/25/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283182
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,925.11 07/23/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282954
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,867.80 07/02/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282156
Principal investigator 1 ARGENX US, INC. $26.50 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155482
Principal investigator 1 ARGENX US, INC. $159.00 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155486
Principal investigator 1 ARGENX US, INC. $37.60 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155489
Principal investigator 1 ARGENX US, INC. $214.80 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155494
Principal investigator 1 ARGENX US, INC. $35.80 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155497
Principal investigator 1 ARGENX US, INC. $573.00 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155503
Principal investigator 1 ARGENX US, INC. $382.00 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155507
Principal investigator 1 ARGENX US, INC. $7.70 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155510
Principal investigator 1 ARGENX US, INC. $5.25 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155513
Principal investigator 1 ARGENX US, INC. $2.80 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155517
Principal investigator 1 ARGENX US, INC. $258.00 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155521
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155525
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155529
Principal investigator 1 ARGENX US, INC. $85.40 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155532
Principal investigator 1 ARGENX US, INC. $191.00 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155536
Principal investigator 1 ARGENX US, INC. $26.50 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155540
Principal investigator 1 ARGENX US, INC. $517.50 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155542
Principal investigator 1 ARGENX US, INC. $668.50 06/18/2025 Non-covered Recipient Entity
Novel Research, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237155547
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,500.00 06/03/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190312299
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $1,345.00 05/12/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527539
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $460.00 05/12/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527545
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $460.00 05/12/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527552
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,949.61 04/01/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190311943
Principal investigator 1 Novartis Pharmaceuticals Corporation $148,936.30 03/25/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) No dispute reported 06/30/2026 1190311941
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,000.00 03/12/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223276333
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,312.76 02/05/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) No dispute reported 06/30/2026 1190312295
Principal investigator 1 Novartis Pharmaceuticals Corporation $184,565.00 01/21/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) No dispute reported 06/30/2026 1190312297
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,297.82 01/09/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190311935
Principal investigator 1 Novartis Pharmaceuticals Corporation $126,035.00 01/06/2025 Non-covered Recipient Entity
NOVEL RESEARCH LLC
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190312293